ID   KP-MRT-KSa
AC   CVCL_A2FP
SY   Kyoto Pediatrics-Malignant Rhabdoid Tumor-KS ascites
DR   cancercelllines; CVCL_A2FP
DR   Wikidata; Q105509815
RX   PubMed=33109553;
CC   Population: Japanese.
CC   Doubling time: ~48 hours (PubMed=33109553).
CC   Karyotypic information: Has a diploid karyotype with a few chromosomal abnormalities (PubMed=33109553).
CC   Sequence variation: Mutation; HGNC; HGNC:11103; SMARCB1; Simple; p.Arg53Ter (c.157C>T); ClinVar=VCV000944246; Zygosity=Heterozygous (PubMed=33109553).
CC   Sequence variation: Mutation; HGNC; HGNC:11103; SMARCB1; Simple; p.Arg190Profs*27 (c.551_569dup19); Zygosity=Heterozygous (PubMed=33109553).
CC   Omics: Genomics; DNA methylation analysis.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C6586; Extrarenal rhabdoid tumor
DI   ORDO; Orphanet_69077; Rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A2FN ! KP-MRT-KS
SX   Female
AG   7M
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 10-04-25; Version: 8
//
RX   PubMed=33109553; DOI=10.21873/anticanres.14636;
RA   Kuwahara Y., Iehara T., Ichise E., Katsumi Y., Ouchi K., Tsuchiya K.,
RA   Miyachi M., Konishi E., Sasajima H., Nakamura S., Fumino S.,
RA   Tajiri T., Johann P.D., Fruhwald M.C., Yoshida T., Okuda T.,
RA   Hosoi H.;
RT   "Novel two MRT cell lines established from multiple sites of a
RT   synchronous MRT patient.";
RL   Anticancer Res. 40:6159-6170(2020).
//